FBLG FIBROBIOLOGICS INC.

FibroBiologics Announces 2024 Annual Meeting of Stockholders

FibroBiologics Announces 2024 Annual Meeting of Stockholders

HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2024 Annual Meeting of Stockholders will take place on August 27, 2024, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is July 1, 2024.

About FibroBiologics

Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit 

General Inquiries:

Investor Relations:

Nic Johnson

Russo Partners

212-845-4242

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697



EN
15/05/2024

Underlying

FBLGFIBROBIOLOGICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIBROBIOLOGICS INC.

 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Reports Second Quarter 2025 Financial Results and Provi...

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update. Recent Highlights Successfully closed third $5 million tranche of a $25 million total financing, wi...

July 31, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Files Patent for Methods of Generating Multipotent Cell...

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts f...

July 28, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics to Present at the Advanced Wound Care Summit USA

FibroBiologics to Present at the Advanced Wound Care Summit USA HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Advanced Wound Care Summit USA in Boston, Massachusetts, on July 15, 2025. The presentation will include recent research a...

July 11, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenera...

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced an advancement in its cartilage repair program. FibroBiologics has confirmed, through both immunohistochem...

July 9, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A ...

FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors to a webinar on July 10, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature FibroBiologics’ Founder and Chief Executive Off...

July 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch